

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNQ HOLDINGS LIMITED

优趣汇控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 2177)

CONTINUING CONNECTED TRANSACTIONS

RENEWAL OF PRODUCTS PROCUREMENT FRAMEWORK AGREEMENT

On 31 October 2025, the Company (for itself and on behalf of the Group) and TCI (for itself and on behalf of the TCI Group) agreed to renew the 2023 Products Procurement Framework Agreement by entering into the 2026 Products Procurement Framework Agreement.

LISTING RULES IMPLICATIONS

As at the date of this announcement, TCI held approximately 34.52% of the total issued Shares and is one of the controlling shareholders of the Company, and thus TCI and its associates are connected persons of the Company. Therefore, the transactions contemplated under the 2026 Products Procurement Framework Agreement constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

As the highest applicable percentage ratio (as defined under the Listing Rules) in respect of the highest proposed annual cap under the 2026 Products Procurement Framework Agreement is more than 5%, the transactions contemplated thereunder are therefore subject to annual reporting, announcement, and independent Shareholders' approval requirements under Chapter 14A of the Listing Rules.

The Independent Board Committee has been formed to provide recommendation to the independent Shareholders in respect of the 2026 Products Procurement Framework Agreement and the transactions contemplated thereunder. DL Securities has been appointed as the Independent Financial Adviser to advise the Independent Board Committee and the independent Shareholders in this regard.

A circular containing, among other things, (i) details of the transactions contemplated under the 2026 Products Procurement Framework Agreement that are subject to annual reporting,

announcement, and independent Shareholders' approval requirements under Chapter 14A of the Listing Rules; (ii) a letter of recommendation from the Independent Board Committee to the independent Shareholders; (iii) a letter of recommendation from DL Securities to the Independent Board Committee and independent Shareholders; and (iv) the notice of the EGM, will be dispatched to Shareholders by no later than 28 November 2025 as additional time is required to prepare and finalize the relevant information to be included in the circular.

RENEWAL OF THE 2023 PRODUCTS PROCUREMENT FRAMEWORK AGREEMENT

On 31 October 2025, the Company (for itself and on behalf of the Group) and TCI (for itself and on behalf of the TCI Group) agreed to renew the 2023 Products Procurement Framework Agreement by entering into the 2026 Products Procurement Framework Agreement.

Principal terms of the 2026 Products Procurement Framework Agreement

(1) *Date*

31 October 2025

(2) *Parties*

- i TCI (for and on behalf of the TCI Group); and
- ii the Company (for and on behalf of the Group)

(3) *Term*

From 1 January 2026 to 31 December 2028

(4) *Subject Matter*

Pursuant to the 2026 Products Procurement Framework Agreement, the Group agrees to purchase, and the TCI Group agrees to sell, certain products manufactured by various Japanese brand partners and introduced by TCI Group to the Company, including but not limited to the OTC drugs and healthcare products under the brands of Nichiban, Ohta's Isan, Taisho, Santen, Daiichi Sankyo, LOXONIN, Senju and Zeria (the "**Products**"). While separate sale and purchase agreements will be entered into between the TCI Group and the Group under the 2026 Products Procurement Framework Agreement to provide detailed terms in respect of delivery, warranty, etc., such sale and purchase agreements shall be subject to applicable laws, regulatory rules of the places where the shares of the parties are listed, and internal corporate governance policies of the parties, and shall not contravene the provisions of the 2026 Products Procurement Framework Agreement.

(5) ***Pricing basis and pricing policies***

The consideration paid by the Group for the procurement under the 2026 Products Procurement Framework Agreement will be charged on a cost-plus basis with the mark-up rate no more than 8% which is determined by arm's length negotiation between the parties taking into account the TCI Group's cost of development and maintenance of relationship of brand partners in Japan, with reference to the prevailing mark-up rates for such kind of transactions in the market. The business departments of the Company shall review product list and mark-up rates offered by TCI Group from time to time, taking into account factors including market prospects, procurement quantity and profitability of the products offered by TCI Group. The senior management of the business departments of the Company will estimate the profit margin prior to entering into definitive agreements with TCI Group taking into account the expected sales price of the Products, consideration to be paid by the Group to TCI Group for such procurement, and any other applicable expenses and costs borne by the Group and assess whether such estimated profit margin will be around or above the average profit margin of the Group's overall sales (the "**Average Profit Margin**"). In the event that mark-up rates offered by the TCI Group would not allow the Company to have a reasonable profit margin around or above the Average Profit Margin, the Company shall not procure such products from TCI Group and will re-negotiate mark-up rates with TCI Group.

The brand partners of the Products, TCI Group and the Group (the "**Relevant Parties**") have been cooperating under the existing business model since Relevant Parties first commenced such cooperation in 2018. Taking into account (i) the quotations and terms offered by three independent suppliers who are capable of fulfilling the Product demand of the Group, in respect of the Products, are not more favorable to the Group than those offered by TCI Group; (ii) the mark-up rates mainly consist of the cost borne by TCI Group to maintain business relationship with brand partners of the Products which are basically comparable with the overall business partner maintenance costs of the Group; (iii) the mark-up rates have been stable since Relevant Parties first commenced such cooperation and are expected to be stable under the 2026 Products Procurement Framework Agreement; and (iv) the Group has a long-term and stable business relationship with TCI Group who is familiar with the Group's requirements and business operation. The Products have been provided by TCI Group in high and stable quality standards and TCI Group could also ensure punctual delivery of sufficient amounts of the Products even during peak seasons which benefits the smooth business operations of the Group. Therefore, the Board is of the view that the transactions contemplated under the 2026 Products Procurement Framework Agreement are on under normal commercial terms.

(6) ***Payment arrangement***

Separate sale and purchase agreements will be entered into between the TCI Group and the Company under the 2026 Products Procurement Framework Agreement, which will set out the precise payment method, time of the payment and other details of the arrangements.

Historical Amounts

The historical transaction amounts of the transactions contemplated under the 2023 Products Procurement Framework Agreement in respect of the Products for the two years ended 31 December 2024 and for the nine months ended 30 September 2025 were approximately RMB54.96 million, RMB35.63 million and RMB54.11 million, respectively.

Proposed Annual Caps and Basis of Determination

In respect of the 2026 Products Procurement Framework Agreement, the proposed annual caps are set out in the table below:

	Proposed annual caps for the year ending 31 December		
	2026	2027	2028
	<i>(RMB in thousands)</i>		
Consideration for the purchase of Products from the TCI Group	200,000	250,000	300,000

When estimating the proposed annual caps for the three years ending 31 December 2028, the Directors have taken into account (i) the historical transaction amounts in respect of the Products under the 2023 Products Procurement Framework Agreement; (ii) the anticipated sales volume of the Products, considering that (a) based on the Group's experience, it is expected that the sales volume of the Products via the Company's existing e-commerce platforms will continue to grow steadily; (b) the potential introduction of new retail channel on certain social platforms, which, if realized, is expected to significantly enhance the sales of the Products; (c) the Company plans to further diversify and enrich Japanese branded product offerings and therefore expects to purchase more Products under the 2026 Products Procurement Framework Agreement; and (d) the anticipated continuous increase in sales volume of healthcare-related products, driven by the growing public awareness and demand for health and wellness solutions.

REASONS FOR AND BENEFITS OF ENTERING INTO THE 2026 PRODUCTS PROCUREMENT FRAMEWORK AGREEMENT

The Directors are of the view that (i) the purchase of the Products manufactured by new brand partners developed and introduced by the TCI Group to the Company will strengthen the Company's ability to continue broadening and diversifying the Company's brand portfolio and expand the Products offering beyond beauty and personal care categories, which help the Company maintain its competitive in the market; (ii) TCI, as a company listed on the Tokyo Stock Exchange, is a reputable market player in Japan. Through such procurement arrangement, the Company is able to leverage the TCI Group's network in Japan to get access to a wide range of Japanese brand partners, particularly those offering branded OTC drugs; (iii) after years of cooperation with the Company, the TCI Group has developed an adequate understanding of the brand portfolio, capital structure and business operations of the Company, which facilitates the introduction of appropriate brand partners by the TCI Group to the Company; and (iv) given that the Company cannot directly procure Nichiban, Ohta's Isan, Taisho, Santen, Daiichi Sankyo, LOXONIN, Senju and Zeria branded OTC drugs from brand partners due to the stringent criteria upheld by numerous Japanese OTC pharmaceutical firms for new business engagements, TCI Group's relationship with those brand partners helps the Company get access to the products of those brands.

CONFIRMATION BY THE DIRECTORS

The Directors (excluding the independent non-executive Directors whose view will be disclosed in the circular) consider that it is in the interests of the Company and its Shareholders as a whole to enter into the 2026 Products Procurement Framework Agreement, the terms thereunder are fair and reasonable and the transactions contemplated thereunder (including the proposed annual caps as set out in the 2026 Products Procurement Framework Agreement) are on normal commercial terms and in the ordinary and usual course of business of the Company.

Mr. NAKAYAMA Kokkei, being a non-executive Director, acts as a senior management in the TCI Group and has therefore abstained from voting on the relevant Board resolution approving the 2026 Products Procurement Framework Agreement. Save as disclosed above, none of the other Directors has material interests in the transactions contemplated thereunder.

INFORMATION OF THE PARTIES

The Group

The Group is a leading brand e-commerce service provider in China, focusing on fast-moving consumer goods, consisting of, among others, personal care products, beauty products, health products and others.

TCI

TCI is a company incorporated under the laws of Japan, whose shares are listed on the Tokyo Stock Exchange under the stock code of 9715, and is one of the controlling shareholders of the Company. TCI's principal business includes business process outsourcing services, contact centre services, e-commerce on-stop services and digital marketing services.

INTERNAL CONTROL PROCEDURES

The Group has maintained an independent finance department and an independent internal control department. In order to ensure that the terms under the 2026 Products Procurement Framework Agreement for the continuing connected transactions are fair and reasonable, no less favourable to the Group than terms available to or from Independent Third Parties, and are carried out under normal commercial terms, the Group has adopted the following internal control procedures:

- i the Board and business and legal departments of the Company will review the terms and the pricing offered by the TCI Group to the Group under the 2026 Products Procurement Framework Agreement and assess the reasonableness and fairness of the mark-up rates every half year. If the Board and business departments are of the opinion that the mark-up rates offered by the TCI Group would not allow the Group to have a reasonable profit margin, the Group will either negotiate with TCI Group to lower the price and/or offer such more favourable terms, or not make such purchase;

- ii the business management team of the Company will closely monitor the products provided by the TCI Group to the Group in connection with the 2026 Products Procurement Framework Agreement, to ensure that the TCI Group's performance under the 2026 Products Procurement Framework Agreement is in compliance with the provisions specified therein;
- iii on an annual basis, the auditors of the Company will check and confirm that the transactions under the 2026 Products Procurement Framework Agreement are carried out in accordance with the Company's pricing policies and such agreement and approved by the Board, and the transactions under the 2026 Products Procurement Framework Agreement will not exceed the annual caps for that relevant year; and
- iv the independent non-executive Directors and auditors of the Company will conduct annual reviews of the continuing connected transactions under the 2026 Products Procurement Framework Agreement and provide annual confirmation to ensure that, in accordance with the Listing Rules, the transactions are conducted in accordance with the terms of the 2026 Products Procurement Framework Agreement.

LISTING RULES IMPLICATIONS

As at the date of this announcement, TCI held approximately 34.52% of the total issued Shares and is one of the controlling shareholders of the Company, and thus TCI and its associates are connected persons of the Company. Therefore, the transactions contemplated under the 2026 Products Procurement Framework Agreement constitute continuing connected transactions of the Company under the Chapter 14A of the Listing Rules.

As the highest applicable percentage ratio (as defined under the Listing Rules) in respect of the highest proposed annual cap under the 2026 Products Procurement Framework Agreement is more than 5%, the transactions contemplated thereunder are therefore subject to annual reporting, announcement, and independent Shareholders' approval requirements under Chapter 14A of the Listing Rules.

The Independent Board Committee has been formed to provide recommendation to the independent Shareholders in respect of the 2026 Products Procurement Framework Agreement and the transactions contemplated thereunder. DL Securities has been appointed as the Independent Financial Adviser to advise the Independent Board Committee and the independent Shareholders in this regard.

DISPATCH OF CIRCULAR

A circular containing, among other things, (i) details of the transactions contemplated under the 2026 Products Procurement Framework Agreement that are subject to annual reporting, announcement, and independent Shareholders' approval requirements under Chapter 14A of the Listing Rules; (ii) a letter of recommendation from the Independent Board Committee to the independent Shareholders; (iii) a letter of recommendation from DL Securities to the Independent Board Committee and independent Shareholders; and (iv) the notice of the EGM, will be dispatched to Shareholders by no later than 28 November 2025 as additional time is required to prepare and finalize the relevant information to be included in the circular.

DEFINITIONS

“2023 Products Procurement Framework Agreement”	a framework agreement entered into between the Company (for itself and on behalf of the Group) and TCI (for itself and on behalf of the TCI Group) on 31 October 2022, pursuant to which the Group would purchase products from the TCI Group
“2026 Products Procurement Framework Agreement”	a framework agreement entered into between the Company (for itself and on behalf of the Group) and TCI (for itself and on behalf of the TCI Group) on 31 October 2025, pursuant to which the Group will purchase products from the TCI Group
“Board”	the board of Directors
“Company”	UNQ Holdings Limited (优趣汇控股有限公司), an exempted company incorporated in the Cayman Islands with limited liability on 31 October 2019
“connected person(s)”	has the meaning ascribed thereto under the Listing Rules
“controlling shareholder”	has the meaning ascribed thereto under the Listing Rules
“Daiichi Sankyo”	Daiichi Sankyo Company Limited, a company headquartered in Japan, whose shares are listed on the Tokyo Stock Exchange under the stock code of 4568, and its subsidiaries, consolidated affiliated entities and/or authorized distributors from time to time, or, as the context requires, the brand Daiichi Sankyo
“Director(s)”	the director(s) of the Company
“EGM”	the extraordinary general meeting of the Company to be convened to consider and, if thought fit, approve, among other things, the 2026 Products Procurement Framework Agreement, the transactions contemplated thereunder (including the proposed annual caps as set out in the 2026 Products Procurement Framework Agreement), or any adjournment thereof
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Independent Board Committee”	an independent committee of the Board comprising all independent non-executive Directors, namely, Dr. NG Kam Wah Webster, Mr. WEI Hang and Ms. XIN Honghua, to advise the independent Shareholders in respect of the 2026 Products Procurement Framework Agreement (including the proposed annual caps for each of the three years ending 31 December 2028)

“Independent Financial Adviser” or “DL Securities”	DL Securities (HK) Limited, a corporation licensed under the SFO to conduct Type 1 (dealing in securities), Type 4 (advising on Securities) and Type 6 (advising on corporate finance) regulated activities as defined under the SFO, being the independent financial adviser to be appointed by the Company to advise the Independent Board Committee and the independent Shareholders in relation to the 2026 Products Procurement Framework Agreement and the transactions contemplated thereunder
“Independent Third Party(ies)”	independent third party(ies) who is/are not connected person(s) and is/are not connected person(s) of the Company
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“LOXONIN”	the brand under Daiichi Sankyo
“Nichiban”	Nichiban Co., Ltd., a company headquartered in Japan, whose shares are listed on the Tokyo Stock Exchange under the stock code of 4218, and its subsidiaries, consolidated affiliated entities and/or authorized distributors from time to time, or, as the context requires, the brand Nichiban
“Ohta’s Isan”	OHTA'S ISAN Co., Ltd., a company headquartered in Japan, and its subsidiaries, consolidated affiliated entities and/or authorized distributors from time to time, or, as the context requires, the brand Ohta’s Isan
“PRC”	the People’s Republic of China
“RMB”	Renminbi, the lawful currency of the PRC
“Santen”	Santen Pharmaceutical Co., Ltd., a company headquartered in Japan, whose shares are listed on the Tokyo Stock Exchange under the stock code of 4536, and its subsidiaries, consolidated affiliated entities and/or authorized distributors from time to time, or, as the context requires, the brand Santen
“Senju”	Senju Pharmaceutical Co.,Ltd., a company headquartered in Japan, and its subsidiaries, consolidated affiliated entities and/or authorized distributors from time to time, or, as the context requires, the brand Senju
“Share(s)”	ordinary share(s) in the share capital of the Company with a par value of HK\$0.0001 each
“Shareholder(s)”	holder(s) of the share(s) of the Company

“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiary(ies)”	has the meaning ascribed to it under the Listing Rules
“Taisho”	Taisho Pharmaceutical Holdings Co., Ltd., and its subsidiaries, consolidated affiliated entities and/or authorized distributors from time to time, or, as the context requires, the brand Taisho
“TCI”	Transcosmos Inc. (大宇宙株式會社), a company incorporated under the laws of Japan, whose shares are listed on the Tokyo Stock Exchange under the stock code of 9715, and one of the controlling shareholders of the Company
“TCI Group”	TCI and its subsidiaries from time to time
“Zeria”	Zeria Pharmaceutical Co., Ltd., a company headquartered in Japan, whose shares are listed on the Tokyo Stock Exchange under the stock code of 4559, and its subsidiaries, consolidated affiliated entities and/or authorized distributors from time to time, or, as the context requires, the brand Zeria
“%”	per cent

By order of the Board
UNQ HOLDINGS LIMITED
WANG Yong
Chairman

Hong Kong, 31 October 2025

As of the date of this announcement, the executive Directors are Mr. WANG Yong, Mr. SHEN Yu and Ms. CHEN Weiwei; the non-executive Director is Mr. NAKAYAMA Kokkei; and the independent non-executive Directors are Dr. NG Kam Wah Webster, Mr. WEI Hang and Ms. XIN Honghua.